164 related articles for article (PubMed ID: 24309600)
1. Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
Robert G; Chappé C; Taque S; Bruneau B; Gandemer V
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e100-2. PubMed ID: 24309600
[TBL] [Abstract][Full Text] [Related]
2. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
Janeway KA; Grier HE
Lancet Oncol; 2010 Jul; 11(7):670-8. PubMed ID: 20347613
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide-induced encephalopathy and movement disorder.
Ames B; Lewis LD; Chaffee S; Kim J; Morse R
Pediatr Blood Cancer; 2010 Apr; 54(4):624-6. PubMed ID: 19953647
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide induced encephalopathy in a child with osteosarcoma.
Sarbay H; Demir ÜF; Yılmaz G; Atay AA; Malbora B
J Oncol Pharm Pract; 2021 Jul; 27(5):1302-1306. PubMed ID: 33023384
[TBL] [Abstract][Full Text] [Related]
5. [A case of subacute transient cerebral dysfunction in a osteosarcoma patient following high-dose methotrexate].
Yamada K; Takahashi M; Yoshida M
Gan To Kagaku Ryoho; 2002 Mar; 29(3):469-72. PubMed ID: 11915742
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.
Michelagnoli MP; Lewis IJ; Gattamaneni HR; Bailey CC; Lashford LS
Br J Cancer; 1999 Mar; 79(7-8):1174-8. PubMed ID: 10098754
[TBL] [Abstract][Full Text] [Related]
7. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
11. [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Hirota T; Takeuchi M; Iwata A; Kitagawa S; Sato T; Konno K; Sawada K; Kobayashi S; Hamaguchi N; Agata H; Katano N; Fujimoto T
Gan To Kagaku Ryoho; 1998 Feb; 25(3):385-90. PubMed ID: 9492832
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
[TBL] [Abstract][Full Text] [Related]
13. Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases.
Duflot T; Marie-Cardine A; Verstuyft C; Filhon B; Pereira T; Massy-Guillemant N; Joannidès R; Bellien J; Lamoureux F
Fundam Clin Pharmacol; 2018 Jun; 32(3):337-342. PubMed ID: 29319893
[TBL] [Abstract][Full Text] [Related]
14. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
Cohen IJ
Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
[TBL] [Abstract][Full Text] [Related]
15. Transient encephalopathy during the late course of treatment with high-dose methotrexate.
Fritsch G; Urban C
Cancer; 1984 May; 53(9):1849-51. PubMed ID: 6584197
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue.
Küpfer A; Aeschlimann C; Wermuth B; Cerny T
Lancet; 1994 Mar; 343(8900):763-4. PubMed ID: 7510815
[TBL] [Abstract][Full Text] [Related]
17. Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings.
Dicuonzo F; Salvati A; Palma M; Lefons V; Lasalandra G; De Leonardis F; Santoro N
J Child Neurol; 2009 Aug; 24(8):1013-8. PubMed ID: 19307676
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
[TBL] [Abstract][Full Text] [Related]
20. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
